Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug SalesInvestors Business Daily • 02/15/23
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionBusiness Wire • 02/06/23
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionGlobeNewsWire • 02/06/23
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines AgencyGlobeNewsWire • 01/26/23
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?The Motley Fool • 01/25/23
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy RichThe Motley Fool • 01/17/23
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer's Drug AduhelmWSJ • 01/10/23
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?The Motley Fool • 01/10/23
Biogen Inc. (BIIB) 41st Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/09/23